Clinical Trials
158 trialsCD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
National Institutes of Health Clinical Center (CC)
MK-1026-003
Merck Sharp & Dohme LLC
A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies
MacroGenics
Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia
St. Jude Children's Research Hospital
ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL
Dana-Farber Cancer Institute
CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR)
Baylor College of Medicine
Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure
AstraZeneca
Soundtrack-E
AstraZeneca
ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL
Newave Pharmaceutical Inc
Universal CAR-T Cells (REVO-UWD-19) for Refractory and Relapsed B-Cell Tumors
Wondercel Biotech (ShenZhen)
Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation
National Institutes of Health Clinical Center (CC)
TITANium
AstraZeneca
CLL17
German CLL Study Group
PCI-32765 for Special Cases of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
National Institutes of Health Clinical Center (CC)
CAR-T Immunotherapy Targeting CD19- ALL
Shenzhen Geno-Immune Medical Institute
BRUIN-CLL-314
Eli Lilly and Company
OPAL
AVM Biotechnology Inc
U96-CAR-T-Cells For R/R B-ALL
The First Affiliated Hospital of Soochow University
CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies
British Columbia Cancer Agency
SOUNDTRACK-C1
AstraZeneca
CLL-IMPACT
Technical University of Munich
ACCESS
Center for International Blood and Marrow Transplant Research
ACCELERATE
Center for International Blood and Marrow Transplant Research
A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
Ossium Health, Inc.
OPTIMIZE
Center for International Blood and Marrow Transplant Research
BaseCAR-01
University Hospital, Basel, Switzerland
CASEY
Baylor College of Medicine
CD22 Redirected Autologous T Cells for ALL
University of Pennsylvania
A Phase 1 Study of ZE50-0134 in Relapsed and Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Select Low-grad Lymphomas
Lomond Therapeutics Holdings, Inc.
Clinical Study Aiming to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Administration of ZE50-0134 at 5 Dose Levels in Healthy Volunteers
Lomond Therapeutics Holdings, Inc.
Preemptive Therapy for High Risk Chronic Lymphoid Leukemia Stage A
French Innovative Leukemia Organisation
CARPASCIO
Baylor College of Medicine
TRICAR-ALL
Baylor College of Medicine
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.
Pharmacyclics Switzerland GmbH
A Phase Ib Study of the Selective PKC-β Inhibitor MS-553 in Patients With Refractory or Relapsed CLL/SLL
MingSight Pharmaceuticals, Inc
A Phase I/II Multiple Center Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Malignancies
Shenzhen Geno-Immune Medical Institute
Combination CAR-T Cell Therapy Targeting Hematological Malignancies
Shenzhen Geno-Immune Medical Institute
ARQ 531-101
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Safety and Feasibility of CD19 CAR T Cells Using CliniMACS Prodigy for Relapsed/Refractory CD19 Positive ALL and NHL
Nationwide Children's Hospital
PIPOZA
Peter MacCallum Cancer Centre, Australia
A Pediatric Trial of Genetically Modified Autologous T Cells Directed Against CD19 for Relapsed CD19+ Acute Lymphoblastic Leukemia
Seattle Children's Hospital
CLL2-BZAG
German CLL Study Group
CLL-Frail
German CLL Study Group
CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
National Institutes of Health Clinical Center (CC)
CLL1818
Gruppo Italiano Malattie EMatologiche dell'Adulto
Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers
AbbVie
CAR2219 CAR-T Cells for the Treatment of R/R B Cell Leukemia and Lymphoma
Affiliated Hospital to Academy of Military Medical Sciences
ACALLO
Polish Lymphoma Research Group
Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas
Zhejiang DTRM Biopharma
VTB-CLL002
Vitebsk Regional Clinical Cancer Centre